FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051002936> ?p ?o ?g. }

• W2051002936 endingPage "841" @default.
• W2051002936 startingPage "834" @default.
• W2051002936 abstract "Background. The authors compared the pharmacokinetics of doxorubicin when administered with and without concomitant high dose cyclosporine for multidrug resistant (MDR) tumor modulation in small cell lung cancer. Methods. Eight patients with small cell lung cancer served as their own controls and were studied first during an initial course of doxorubicin without cyclosporine, and then subsequently during a cyclosporine-modulated doxorubicin course. All patients received cyclophosphamide and vincristine in each course. Doxorubicin was administered as a 1-hour infusion after a 2-hour cyclosporine loading infusion, and cyclosporine was infused continuously for the next 48 hours. Serum concentrations of doxorubicin, doxorubicinol, and cyclosporine all were assayed by high-pressure liquid chromatography. Pharmacokinetic analysis of doxorubicin included area under the curve (AUC), clearance, apparent volume of distribution at steady state (Vss), and elimination halflife (T.50). The percent of change and surviving fraction of leukocyte count and platelets were determined as pharmacodynamic indices. Results. Cyclosporine modulation increased the AUC0-36 of doxorubicinol by 48% (P = 0.042) and the AUC0-36 of doxorubicinol by 443% (P = 0.0001), whereas the doxorubicin clearance declined by 37% (P = 0.0495). No difference was found in the Vss or T.50 for doxorubicin when cyclosporine was added to the regimen. The ratio of the doxorubicinol AUC0-36 to the doxorubicin AUC0-36 increased significantly with cyclosporine modulation (8.88 vs. 2.19; P = 0.001). Drug-related toxicity was also greater with the cyclosporine-modulated course of doxorubicin. A 91% reduction in the leukocyte count followed the modified course, compared with an 84% reduction following the initial course (P = 0.0074). A more prolonged and greater degree of myelosuppression was observed and a significant relationship was found between the systemic exposure to doxorubucin (defined by AUC) and the surviving fraction of the leukocyte count (r = -0.69; P = 0.006). Similarly, the reduction in the platelet count was significantly greater after the cyclosporinemodulated course (72.8%) than after the initial course (36.4%) (P = 0.0016). A significant correlation was found between the AUC of doxorubicinol and the surviving fraction of platelets (r = -0.71; P = 0.004). In addition, patients showed decreased performance status associated with significant weight loss and severe myalgias. Conclusions. The addition of high dose cyclosporine for MDR modulation resulted in the significant alteration of doxorubicin disposition and remarkable toxicity in all patients. The mechanisms responsible for the decreased doxorubicin clearance may include cyclosporine's ability both to interfere with P-glycoprotein in normal tissues and to selectively inhibit the cytochrome P-450 enzyme system. Further study of this potentially significant drugdrug interaction is warranted." @default.
• W2051002936 created "2016-06-24" @default.
• W2051002936 creator A5036766883 @default.
• W2051002936 creator A5055269054 @default.
• W2051002936 creator A5063738784 @default.
• W2051002936 creator A5077041451 @default.
• W2051002936 creator A5081984076 @default.
• W2051002936 creator A5091651627 @default.
• W2051002936 date "1994-08-01" @default.
• W2051002936 modified "2023-10-11" @default.
• W2051002936 title "The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer" @default.
• W2051002936 cites W1773381463 @default.
• W2051002936 cites W1927327874 @default.
• W2051002936 cites W1958840615 @default.
• W2051002936 cites W1963786241 @default.
• W2051002936 cites W1965296316 @default.
• W2051002936 cites W1971055178 @default.
• W2051002936 cites W1981999275 @default.
• W2051002936 cites W1994826152 @default.
• W2051002936 cites W1997364324 @default.
• W2051002936 cites W2011247555 @default.
• W2051002936 cites W2045485835 @default.
• W2051002936 cites W2070005495 @default.
• W2051002936 cites W2078789226 @default.
• W2051002936 cites W2088419541 @default.
• W2051002936 cites W2132122697 @default.
• W2051002936 cites W2432364308 @default.
• W2051002936 cites W2502670554 @default.
• W2051002936 cites W4245797813 @default.
• W2051002936 doi "https://doi.org/10.1002/1097-0142(19940801)74:3<834::aid-cncr2820740308>3.0.co;2-9" @default.
• W2051002936 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8039111" @default.
• W2051002936 hasPublicationYear "1994" @default.
• W2051002936 type Work @default.
• W2051002936 sameAs 2051002936 @default.
• W2051002936 citedByCount "75" @default.
• W2051002936 countsByYear W20510029362012 @default.
• W2051002936 countsByYear W20510029362013 @default.
• W2051002936 countsByYear W20510029362014 @default.
• W2051002936 countsByYear W20510029362016 @default.
• W2051002936 countsByYear W20510029362017 @default.
• W2051002936 countsByYear W20510029362018 @default.
• W2051002936 countsByYear W20510029362020 @default.
• W2051002936 countsByYear W20510029362021 @default.
• W2051002936 countsByYear W20510029362022 @default.
• W2051002936 countsByYear W20510029362023 @default.
• W2051002936 crossrefType "journal-article" @default.
• W2051002936 hasAuthorship W2051002936A5036766883 @default.
• W2051002936 hasAuthorship W2051002936A5055269054 @default.
• W2051002936 hasAuthorship W2051002936A5063738784 @default.
• W2051002936 hasAuthorship W2051002936A5077041451 @default.
• W2051002936 hasAuthorship W2051002936A5081984076 @default.
• W2051002936 hasAuthorship W2051002936A5091651627 @default.
• W2051002936 hasBestOaLocation W20510029361 @default.
• W2051002936 hasConcept C111113717 @default.
• W2051002936 hasConcept C112705442 @default.
• W2051002936 hasConcept C126322002 @default.
• W2051002936 hasConcept C126894567 @default.
• W2051002936 hasConcept C139254425 @default.
• W2051002936 hasConcept C2776256026 @default.
• W2051002936 hasConcept C2776694085 @default.
• W2051002936 hasConcept C2776755627 @default.
• W2051002936 hasConcept C2779384505 @default.
• W2051002936 hasConcept C2781303535 @default.
• W2051002936 hasConcept C71924100 @default.
• W2051002936 hasConcept C98274493 @default.
• W2051002936 hasConceptScore W2051002936C111113717 @default.
• W2051002936 hasConceptScore W2051002936C112705442 @default.
• W2051002936 hasConceptScore W2051002936C126322002 @default.
• W2051002936 hasConceptScore W2051002936C126894567 @default.
• W2051002936 hasConceptScore W2051002936C139254425 @default.
• W2051002936 hasConceptScore W2051002936C2776256026 @default.
• W2051002936 hasConceptScore W2051002936C2776694085 @default.
• W2051002936 hasConceptScore W2051002936C2776755627 @default.
• W2051002936 hasConceptScore W2051002936C2779384505 @default.
• W2051002936 hasConceptScore W2051002936C2781303535 @default.
• W2051002936 hasConceptScore W2051002936C71924100 @default.
• W2051002936 hasConceptScore W2051002936C98274493 @default.
• W2051002936 hasIssue "3" @default.
• W2051002936 hasLocation W20510029361 @default.
• W2051002936 hasLocation W20510029362 @default.
• W2051002936 hasOpenAccess W2051002936 @default.
• W2051002936 hasPrimaryLocation W20510029361 @default.
• W2051002936 hasRelatedWork W1982751459 @default.
• W2051002936 hasRelatedWork W2033445329 @default.
• W2051002936 hasRelatedWork W2051812095 @default.
• W2051002936 hasRelatedWork W2067177021 @default.
• W2051002936 hasRelatedWork W2148119941 @default.
• W2051002936 hasRelatedWork W2156393504 @default.
• W2051002936 hasRelatedWork W2364099549 @default.
• W2051002936 hasRelatedWork W2384005405 @default.
• W2051002936 hasRelatedWork W2415638501 @default.
• W2051002936 hasRelatedWork W2440060870 @default.
• W2051002936 hasVolume "74" @default.
• W2051002936 isParatext "false" @default.
• W2051002936 isRetracted "false" @default.
• W2051002936 magId "2051002936" @default.
• W2051002936 workType "article" @default.